Oslo, 27 February 2026: Reference is made to the stock exchange announcements
published on 5 February 2026 and earlier today on 27 February 2026 by EXACT
Therapeutics AS' (the "Company", Euronext Growth ticker: EXTX), a clinical-stage
precision medicine company, regarding the exercise of warrants issued in
conjunction with the private placement completed in December 2024. 

For the purpose of issuing the new shares pursuant to the warrants exercise, an
extraordinary general meeting of the Company will be held as a virtual meeting
on 13 March 2026 at 10:30 hours CET.
 
The notice for the extraordinary general meeting, including the attendance and
proxy forms, is attached to this announcement. The documents are also available
at www.exact-tx.com. The deadline for receiving proxies or attendance
registration is 11 March 2026 at 16:00 CET.

About EXACT Therapeutics: 
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX). 

Further information may be found here:www.exact-tx.com 

For further information, please contact: 
Per Walday 
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com